Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 2/2012

01-02-2012 | Case Report

Interleukin-6-producing dermoid cyst associated with multicentric Castleman’s disease

Authors: Shigeyuki Ebara, Soken-Nakazawa J. Song, Hiroyuki Mizuta, Yasushi Ito, Kenji Hasegawa, Tsuneko Kamata, Teppei Matsumura-Nishikawa, Takafumi Ogawa, Jyunichi Soneda, Kazuyuki Yoshizaki

Published in: International Journal of Hematology | Issue 2/2012

Login to get access

Abstract

Dysregulated overproduction of interleukin-6 (IL-6) from activated B cells in affected lymph nodes has been implicated in the pathogenesis of multicentric Castleman’s disease (MCD), a rare lymphoproliferative disorder accompanied by systemic manifestations. We here report the case of a 32-year-old female presenting with MCD associated with a dermoid cyst in the pelvic cavity. The co-occurrence of MCD and dermoid cyst has not been reported before. Immunohistochemical analysis of the tissue sections showed IL-6 production in CD68-positive macrophage cells, which had infiltrated the dermoid cyst. Removal of the cyst resulted in partial improvement in systemic symptoms accompanied by a decrease in serum IL-6, while complete improvement was obtained by treatment with an anti-IL-6 receptor antibody following resection of the dermoid cyst. To the best of our knowledge, this is the first study to provide evidence of IL-6 production by CD68+ cells in a dermoid cyst involved in MCD.
Literature
1.
Castleman B, Iverson L, Menendze VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9:822–30.PubMedCrossRef
2.
Keller AR, Hochholzer L, Castleman B. Hyalin-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29:670–83.PubMedCrossRef
3.
Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease. Clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol. 1985;3:1202–16.PubMed
4.
Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Lee T, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castelman’s disease. Blood. 1989;74:1360–7.PubMed
5.
Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castelman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95:56–61.PubMed
6.
Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman’s disease. Blood. 2005;106:2627–32.PubMedCrossRef
7.
Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010;116:3627–34.PubMedCrossRef
8.
Naresh KN, Rice AJ, Bower M. Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma. Am J Surg Pathol. 2008;32:1006–12.PubMedCrossRef
9.
Molinié V, Diebold J. Hodgkin’s disease associated with localized or multicentric Castleman’s disease. Arch Pathol Lab Med. 1995;119:201.PubMed
10.
Larroche C, Cacoub P, Soulier J, Oksenhendler E, Clauvel JP, Piette JC, et al. Castleman’s disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol. 2002;69:119–26.PubMedCrossRef
11.
Curioni S, D’Amico M, Quartagno R, Martino S, Dell’Antonio G, Cusi D. Castleman’s disease with nephrotic syndrome, amyloidosis and autoimmune manifestations. Nephrol Dial Transplant. 2001;16:1475–8.PubMedCrossRef
12.
Tavoni A, Vitali C, Baglioni P, Gerli R, Marchetti G, Di Munno O, et al. Multicentric Castleman’s disease in a patient with primary Sjögren’s syndrome. Rheumatol Int. 1993;12:251–3.PubMedCrossRef
13.
Nanki T, Tomiyama J, Arai S. Mixed connective tissue disease associated with multicentric Castleman’s disease. Scand J Rheumatol. 1994;23:215–7.PubMedCrossRef
14.
Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J, et al. Interleukin-6 gene expression in Castleman’s disease. Blood. 1991;78:2923–30.PubMed
15.
Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, et al. Brief report: alleviation of systemic manifestations of Castleman’s disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330(9):602–5.PubMedCrossRef
16.
Zaloude KC. Tumors of ovary. In: Fletcher CDM, editor. Diagnostic histopathology of tumours. 2nd ed. Churchill Livingston: Harcourt Publication Ltd; 2000. p. 611.
17.
Van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98–3936. Leukemia. 2003;17:2257–317.PubMedCrossRef
18.
Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112:3959–64.PubMedCrossRef
19.
20.
Nishikawa T, Hagihara K, Serada S, Isobe T, Matsumura A, Song J, et al. Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J Immunol. 2008;180:3492–501.PubMed
Metadata
Title
Interleukin-6-producing dermoid cyst associated with multicentric Castleman’s disease
Authors
Shigeyuki Ebara
Soken-Nakazawa J. Song
Hiroyuki Mizuta
Yasushi Ito
Kenji Hasegawa
Tsuneko Kamata
Teppei Matsumura-Nishikawa
Takafumi Ogawa
Jyunichi Soneda
Kazuyuki Yoshizaki
Publication date
01-02-2012
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 2/2012
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-011-0978-5

Other articles of this Issue 2/2012

International Journal of Hematology 2/2012 Go to the issue

Progress in Hematology

New functions of the fibrinolytic system in bone marrow cell-derived angiogenesis

Original Article

Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study

Letter to the Editor

Interstitial pneumonitis associated with the immunomodulatory drugs thalidomide and lenalidomide

Review Article

Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: a meta-analysis

Case Report

Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa

Case Report

Posterior reversible encephalopathy syndrome in an adult patient with acute lymphoblastic leukemia after remission induction chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits